




November 30<sup>th</sup> 2018

# Recent Changes in Longevity and their Implications for the Insurance Sector

**Daria Ossipova – Head of Longevity and Health R&D;  
SGL Chief Pricing Officer (interim)**

# Longevity risk

## Historically, scientists have not foretold the continuous increase in average life expectancy




- Historically, numerous experts assumed there was a limit to the average human life expectancy (represented by horizontal lines); observations proved them wrong

- Over the past 150 years life expectancy has increased by one trimester every year on average

Experts have often underestimated progress in longevity


# Life expectancy at 65 has started to change significantly only recently

Age components of changes in life expectancy in France



Insurance Industry realized the importance of longevity risk only in the 21 century...

Cumulative Annual Transaction Totals by Country and Product




Sources: LCP, LIMRA, Hymans Robertson and Prudential analysis, June 2015. Data in USD billions.



# The size of the potential market for longevity transfers is considerable, hence reinsurers must cautiously use their capabilities

## A vast longevity risk transfer potential


10 largest private pension fund schemes by asset size (in USD trillions)<sup>1)</sup>



- Considering approximately 60% of these pension funds are on defined benefits, a total of **~\$16,000 billion carry longevity risk**
- Throughout the past decade, **about \$200 billion obligations were transferred to the UK**, and about \$70 billion to the USA.

## An existing longevity reinsurance market in the UK and North America

Insurance solutions in amount of insured obligations (in USD billions)



- **United Kingdom:** Transactions covering all risks (buy-out or buy-in) or simply biometric (swap)
- **United States:** Transactions covering all risks (buy-out or buy-in)
- **Canada:** Recent swap transactions


## UK longevity risk – where is it?

---

- UK has a long history of Defined Benefit pension schemes (usually Final Salary linked pensions) offered by employers
- E.g. typical scheme offers pension equal to:
  - (years of service) X Final salary / 60
- **Approx. £2trillion of DB pensions liabilities**
- Over last couple of decades, shift to Defined Contribution ('money purchase') pensions
- **Approx. £0.5trillion of DC in-payment annuity liabilities**
- Both sources present opportunities for longevity reinsurance.




# UK - Longevity Market Structural Overview




## Reinsurance: Bulk annuity vs Swap

### Swap



### Bulks annuity



Reinsurance is *usually* a swap for 100% QS of the longevity risk only regardless of whether the original risk transfer is a bulk annuity or swap.

Common terminology for bulk annuities:


'**Buy-in**' – A bulk annuity bought and held by a pension scheme as an asset

'**Buy-out**' – A bulk purchase of individual annuities distributed to pension scheme members





# Reinsurance pricing



# Longevity risk is composed of 3 components; trend is the most material





**Trend risk** + **Level risk** + **Volatility risk** = **Longevity risk**

Risk that mortality rates improve faster than expected

Risk of an inaccurate assessment of current mortality rates

Risk of volatile mortality rates due to insufficient mutualisation, heterogeneous portfolio

Combination of all components




**It is the main risk component, the most material**

# Volatility: influence of portfolio heterogeneity


## Pension amount

Gender	Mean	Standard deviation	Min	Max
Females	3 180	4 348	5	91 188
Males	4 463	5 416	5	75 013



## Distribution of amounts

- 1% of the highest pensions account for 8% of the total volume
- 5% of the highest pensions account for 27% of the total volume
- 10% of the highest pensions account for 41% of the total volume



## L - mortality level component: influence of portfolio heterogeneity


- ❑ Split the portfolio into homogeneous sub-groups :
  - Generally pension size is a good proxy to social class,
  - Keep the number of subgroups limited in order to maintain results significant,
  - Check against external datasets (ex. mortality by postcode).
  
- ❑ Example: 5 subgroups based on pension size . A/E ratio in lives and in amounts

Pension size	A/E (lives)	A/E (amount)	Nb of deaths	Exposure (lives)	Exposure (amount)	% total (lives)	% total (amount)
0 – 3 749	114%	112%	1 812	56 189	85 mln	67%	26%
3 750 – 7 499	98%	98%	263	15 220	81 mln	18%	24%
7 500 +	88%	85%	158	11 891	165 mln	14%	50%

Pension size	A/E (lives)	A/E (amount)	Nb of deaths	Exposure (lives)	Exposure (amount)	% total (lives)	% total (amount)
0 – 2 999	101%	102%	665	26 978	31 mln	73%	31%
3 000 +	86%	72%	115	9 879	70 mln	27%	69%




## T - Trend: Drivers of mortality are evolving




Not all countries undergo the stages at the same time, speed, or even order

T- Trend. A combination of advanced quantitative and qualitative analysis methods is needed to evaluate longevity risk.


### Trends by cause of death



### Mortality improvements based on age/birthyear




Qualitative analysis:  
understanding the numbers





Numerical analysis:  
determining the factors of change

# More complex methods are being developed to include informed judgments




- We decompose the mortality into CoD proportions and CoD mortality densities.
- This approach offers better performance and interpretability.



- Working with CoD proportions and mortality densities provide high flexibility for Expert Judgments inclusion on CoD mortality dynamics. Below two examples:
  - 1 Include the impact of an invention of vaccines or effects resulting from epidemics, by adding a constraint to the CoD proportion
  - 2 Include the impact of new medical treatment delaying the age at death for a CoD, by shifting the density towards the right

# Recent UK mortality improvements were lower than expected

## Males mortality rates observed<sup>1)</sup> and projected



## Key questions raised by the recent observations

- Is this phenomenon a coincidence or a structural change?
- What are the main reasons for this slowdown in Mortality Improvements ?
- Does it impact our longevity book in the same manner as the national population?
- How should we reflect the recent observations in our best estimate (future and past improvements)?




This disruptive phenomenon requires the industry to challenge our view on the UK longevity.



# Analysis by Cause of Death

## SMR<sup>1</sup> by cause, persons aged 75+, E&W, 2001-2015



## Take Away

- Most of the large gains in improvements between 2001 and 2010 were caused by the reduction in Circulatory deaths. Their proportion in total deaths is much lower now so further improvements can not make such significant impact any more in population mortality.
- Dementia and Alzheimer's disease experienced an increase in the past years, however this is partly caused by the aging population and changes in diagnosis practices (e.g. some mental illnesses were classified as Circulatory or Respiratory disease before).
- Cancer and other causes remained on a similar level in the past 15 years.



There is no clear explanation on the improvements slowdown when looking at causes of deaths.

## Behind the trend change: a structural issue

### Winters partially explain the slowdown of mortality improvements

- In the 2012/2013 winter, mortality has been driven by the unusual length of the cold spell.
- The 2014/2015 winter was not unusually cold but the high mortality is believed to have been driven by the lower efficiency rate of the flu vaccine.

### But they hide a bigger structural factor


- The early 2017 deaths figures (even if very provisional) show similar high mortality to the 2015 figures.
- Increasing mortality in the past five years is driven by the oldest age groups (85+).
- Whereas the opinion was split in the past, the industry now agrees that the recent slowdown is very unlikely to be a blip.
- The majority seems to point towards the NHS structural struggles such as the lack of funding and the clogged A&E during winter epidemics.




**The slowdown seems to be a consequence of general population aging and the difficulties of the National Health System rather than the winters themselves.**

# The increasing needs of an ageing population

## The population is getting older ...




## ... and costs multiply with age




The health and social care costs are increasing due to the ageing of the population.

# The funding of health and social care has become insufficient

**A stagnating NHS budget ...**



**... and decreasing social care spending**




The evolution of the care spending is not matching the increasing needs of the ageing population.

## What is the Index of Multiple Deprivation?




An index of the Office of National Statistics allowing the ranking of the 32,844 neighbourhoods in England according to the following factors:




The Office of National Statistics splits the published national deaths and exposures by decile of deprivation over 2001-2015.

# IMD geographical distribution across England



## 2001-2015 UK Mortality Dynamics by Area



ONS is the national population mortality, i.e. aggregation of IMD1 to 5

Flat line indicates that the subpopulation has similar trend to the national population. Increasing/decreasing line indicates that the subpopulation experiences lower/higher mortality improvements than the national population.

The graph relates to the female population, although the same observation applies to males.




The gap between the least and the most deprived has been widening over 2001-2015.

## Overview of competitive landscape in UK - 2018

---

- ❑ Reinsurance transactions in excess of £30bn expected in the UK in 2018
  
- ❑ Virtually all reinsurers are pricing in lower improvement assumptions in the UK compared to 12-18 months ago – some more aggressively than others
  - Increased spread of reinsurer pricing than seen in past years
  - Winning line is back at 4-5% margin for mid to higher duration deals and 3-4% for low duration
  
- ❑ Some reinsurers continue to opportunistically look at asset plus longevity deals





THANK YOU!

